Leukemia AML with t(8.21) ectasia, some early stage patients can achieve clinical cure through timely and effective treatment. However, some patients have a poorer prognosis. Leukemia AML with t(8.21) ectopic belongs to acute myeloid leukemia. Although the prognosis of patients with leukemia AML with t(8.21) is relatively poor, the prognosis will be improved if it is accompanied by KIT gene mutation. One of the most important factors affecting the prognosis of leukemia AML with t(8.21) is age. the complete remission rate of AML patients aged 55-60 years is 60%-80%, with a 5-year survival of 30%-40%, while the complete remission rate of elderly AML aged >60 years is only 40%-55%, and very few patients achieve long-term survival. The outcome of the same disease varies due to the patient’s age, physical fitness, different stages of disease progression, and different treatment methods. If leukemia AML with t (8.21) is diagnosed, early and standardized treatment (cytarabine, Zoerythromycin) under the guidance of a physician is recommended to minimize the adverse effects of the disease.